SVP & Chief Accounting Officer · VERTEX PHARMACEUTICALS INC / MA · Common Stock
Side
A
Value
—
Shares
1,300
Price
—
Executed
Jan 22, 2026
Disclosed
Jan 26, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jan 22 executedJan 26, 2026 disclosed
VRTX · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+5 / 25
No reported dollar value · 12.0% of prior position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Ambrose Kristen filed this Form 4 reporting a grant or award of VRTX on Jan 22, 2026. It became public on Jan 26, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
SVP & Chief Accounting Officer
Ambrose Kristencik:0001856587
Issuer
VERTEX PHARMACEUTICALS INC / MAcik:0000875320
Revision history · 0
No field has changed since this record was first ingested.
